Clinical Trials Browser

Interventional × Skin Neoplasms × relatlimab × Clear all

NCT07459543 2026-03-09

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

Phase 4 Not yet recruiting

Melanoma, Skin Neoplasms